Biodesix, Inc. Stock price

Equities

BDSX

US09075X1081

Healthcare Facilities & Services

Delayed Nasdaq 02:58:14 2024-03-28 pm EDT 5-day change 1st Jan Change
1.43 USD -0.69% Intraday chart for Biodesix, Inc. +5.93% -22.28%
Sales 2024 * 65.25M Sales 2025 * 79.04M Capitalization 140M
Net income 2024 * -39M Net income 2025 * -32M EV / Sales 2024 * 2.14 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.77 x
P/E ratio 2024 *
-3.39 x
P/E ratio 2025 *
-4.43 x
Employees 217
Yield 2024 *
-
Yield 2025 *
-
Free-Float 18.93%
More Fundamentals * Assessed data
Dynamic Chart
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center MT
Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center CI
Transcript : Biodesix, Inc., Q4 2023 Earnings Call, Mar 01, 2024
Biodesix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2024 CI
Earnings Flash (BDSX) BIODESIX Posts Q4 Revenue $14.7M MT
Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method CI
Transcript : Biodesix, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (BDSX) BIODESIX Reports Q3 Revenue $13.5M, vs. Street Est of $14.4M MT
Biodesix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2023 CI
Transcript : Biodesix, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:15 PM
Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer CI
Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer CI
More news
1 day-0.69%
1 week+6.67%
Current month-6.49%
1 month-8.86%
3 months-20.88%
6 months-6.49%
Current year-21.74%
More quotes
1 week
1.32
Extreme 1.32
1.52
1 month
1.32
Extreme 1.32
1.93
Current year
1.32
Extreme 1.32
2.21
1 year
1.03
Extreme 1.03
2.21
3 years
0.96
Extreme 0.955
21.30
5 years
0.96
Extreme 0.955
31.99
10 years
0.96
Extreme 0.955
31.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 -
Director of Finance/CFO 44 11-02-28
Chief Tech/Sci/R&D Officer - 15-12-31
Members of the board TitleAgeSince
Chairman 76 08-05-31
Director/Board Member 83 11-12-31
Director/Board Member 60 21-12-05
More insiders
Date Price Change Volume
24-03-28 1.43 -0.69% 19 953
24-03-27 1.44 -0.69% 30,255
24-03-26 1.45 +0.69% 43,583
24-03-25 1.44 +4.35% 104,529
24-03-22 1.38 +2.22% 86,795

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Biodesix, Inc. (Biodesix) is a data-driven diagnostic solutions company. Biodesix is focused on using technologies with its artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs in lung disease. Biodesix is providing diagnostic testing services associated with blood-based lung tests; coronavirus disease tests and providing biopharmaceutical companies with services that include diagnostic research, clinical research, development, and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Its blood-based lung cancer tests include Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. Biodesix also offers SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralizing Antibody testing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.44 USD
Average target price
3.5 USD
Spread / Average Target
+143.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Biodesix, Inc. - Nasdaq